natgillin/translations-raw huggingface dataset:
Simponi, в комбинация с метотрексат (MTX), е показан за: лечение на умерено тежък до тежък активен ревматоиден артрит при възрастни, когато отговорът на лечението с модифициращи болестта антиревматоидни средства (DMARD), включително и с MTX, не е достатъчен. лечение на тежък, активен и прогресиращ ревматоиден артрит при възрастни, които преди това не са лекувани с MTX.
Simponi, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.
Simponi, самостоятелно или в комбинация с MTX, е показан за лечение на активен и прогресиращ псориатичен артрит при възрастни, когато отговорът на предшестващо лечение с модифициращи болестта DMARD, не е достатъчен.
Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
Simptomi so se pojavili v času od enega dneva do več mesecev po začetku zdravljenja.
The time to onset of symptoms varied from one day to several months after starting treatment.
Simptomi so:
The symptoms include:
Simulect 10 mg прах и разтворител за инжекционен или инфузионен разтвор
Simulect 10 mg powder and solvent for solution for injection or infusion
Simulect 20 mg прах и разтворител за инжекционен или инфузионен разтвор
Simulect 20 mg powder and solvent for solution for injection or infusion
Simulect действа като не позволява на имунните клетки да атакуват трансплантираните органи.
Simulect works by stopping the immune cells that attack transplanted organs.
Simulect може да бъде прилаган на деца и подрастващи.
Simulect can be given to children and adolescents.
Simulect може да бъде прилаган на хора в старческа възраст, но наличната информацията е ограничена.
Simulect can be given to older patients, but the information available is limited.
Simulect не трябва да се прилага, ако не е напълно сигурно, че пациентът ще получи присадката и съпътстващата имуносупресивна терапия.
Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression.
Simulect се въвежда във вена под формата на болус инжекция (приложена наведнъж) или на вливане с продължителност 20 до 30 минути.
Simulect is given into a vein, either as a ‘bolus’ injection (given all at once) or as an infusion over 20 to 30 minutes.
Simulect се доставя и във флакони, съдържащи 10 mg базиликсимаб.
Simulect is also available in vials with 10 mg basiliximab.
Simulect се доставя и във флакони, съдържащи 20 mg базиликсимаб.
Simulect is also available in vials with 20 mg basiliximab.
Simulect се използва в комбинация с други лекарства, употребявани за предотвратяване на отхвърлянето на органи, като циклоспорин, кортикостероиди, азатиоприн и микофенолат мофетил.
Simulect is used in combination with other medicines used to prevent organ rejection, such as ciclosporin, corticosteroids, azathioprine and mycophenolate mofetil.
Simulect се използва при възрастни и деца над една година за предотвратяване отхвърлянето на новотрансплантирани бъбреци от организма.
Simulect is used in adults and children aged over one year, to prevent the body from rejecting a newly transplanted kidney.
Simulect се намира под формата на бял прах в безцветен стъклен флакон, съдържащ 10 mg базиликсимаб.
Simulect comes as a white powder in a colourless glass vial containing 10 mg of basiliximab.
Simulect се намира под формата на бял прах в безцветен, стъклен флакон, съдържащ 20 mg базиликсимаб.
Simulect comes as a white powder in a colourless glass vial containing 20 mg of basiliximab.
Simulect се прилага двукратно, в болница, или бавно през игла във вената Ви като инфузия с продължителност 20-30 минути, или като интравенозна инжекция с помощта на спринцовка.
Simulect is given twice, in hospital, either slowly through a needle in your vein as an infusion lasting 20–30 minutes or as an intravenous injection using a syringe.
Simva 40
0.019
Simva 40
Apo B/Apo AI
simvastatin a lovastatin (používané ke snížení hladiny cholesterolu)
imvastatin and lovastatin (used to lower blood cholesterol).
Simvastatin a lovastatin jsou z hlediska svého metabolizmu vysoce závislé na CYP3A4 a souběžné podávání s přípravkem EVOTAZ může vést ke zvýšení koncentrací.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co- administration with EVOTAZ may result in increased concentrations.
Sindan-Pharma S.R.L.
S.C. Sindan-Pharma S.R.L.
SINDAN-PHARMA S.R.L. 11 Ion Mihalache Blvd.
S.C. SINDAN-PHARMA S.R.L. 11 Ion Mihalache Blvd.
Singapore 637394 Сингапур
Singapore 637394 Singapore
Singapore 637421 Сингапур
Singapore 637421 Singapore
SIRS, синдром на нарушена капилярна пропускливост (признаци и симптоми на освобождаване на цитокинини, например тахипнея, тахикардия, хипотония, белодробен оток) са съобщени като нежелани реакции при 5% (6/115) от педиатричните пациенти (5 ОЛЛ, 1 АМЛ) (вж. точка 4.4).
SIRS, capillary leak syndrome (signs and symptoms of cytokine release, e.g., tachypnea, tachycardia, hypotension, pulmonary oedema) were reported as an adverse event in 5% (6/115) of paediatric patients (5 ALL, 1 AML) (see section 4.4).
SIRTURO 100 mg таблетки бедахилин
SIRTURO 100 mg tablets Bedaquiline
SIRTURO е показан за употреба като част от подходяща комбинирана схема за лечение на белодробна мултирезистентна туберкулоза (multidrug-resistant tuberculosis, MDR-TB) при възрастни пациенти, когато не може да бъде назначена друга ефективна терапия, поради резистентност или толерантност.
SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
Sirturo е разрешен за употреба по т.нар. схема „разрешаване под условие“.
Sirturo has been given ‘conditional approval’.
SIRTURO не е проучван при пациенти с чернодробно увреждане в тежка степен и не се препоръчва при тази популация.
SIRTURO has not been studied in patients with severe hepatic impairment and is not recommended in this population.
SIRTURO с алкохол
SIRTURO with alcohol
Sirturo се използва при възрастни пациенти с белодробна мултирезистентна туберкулоза (резистентна поне към изониазид и рифампицин, две стандартни антитуберкулозни лекарства) в комбинация с други лекарства за лечение на туберкулоза.
Sirturo is used in combination with other tuberculosis medicines in adults with tuberculosis that is affecting the lung and that is multi-drug resistant (resistant to at least isoniazid and rifampicin, two standard tuberculosis medicines).
SIRTURO трябва да се използва в комбинация с най-малко три лекарствени продукта, към които изолатът от пациента е показал чувствителност in vitro.
SIRTURO should be used in combination with at least three medicinal products to which the patient’s isolate has been shown to be susceptible in vitro.
SIRTURO трябва да се използва с повишено внимание при пациенти с чернодробно увреждане в умерена степен (вж. точка 5.2).
SIRTURO should be used with caution in patients with moderate hepatic impairment (see section 5.2).
Sistem za dovajanje dušikovega oksida za predihavanje s prekinitvami pretoka bi moral te dvige koncentracije dušikovega oksida ustrezno odpraviti.
The nitric oxide delivery system for intermittent flow ventilation should be adequate to avoid spikes in nitric oxide concentration.
Sistem za dovajanje mora zagotavljati stalno koncentracijo vdihanega zdravila INOmax, ne glede na respirator.
The delivery system must provide a constant inhaled INOmax concentration irrespective of the ventilator.
Sistemska izpostavljenost ustekinumabu (Cmax in AUC) po enkratni intravenski injekciji odmerkov od 0,09 mg/kg do 4,5 mg/kg je naraščala približno sorazmerno z odmerkom.
The systemic exposure of ustekinumab (Cmax and AUC) increased in an approximately dose-proportional manner after a single intravenous administration at doses ranging from 0.09 mg/kg to 4.5 mg/kg.
Sitaxentan sodium(Натриев ситаксентан)
Sitaxentan sodium
Sivextro 200 mg прах за концентрат тедизолидов фосфат
Sivextro 200 mg powder for concentrate tedizolid phosphate
Sivextro 200 mg филмирани таблетки тедизолидов фосфат
Sivextro 200 mg film-coated tablets tedizolid phosphate
Sivextro е бял, до почти бял прах за концентрат за инфузионен разтвор в стъклен флакон.
Sivextro is a white to off-white powder for concentrate for solution for infusion in a glass vial.
Sivextro е овална, жълта филмирана таблетка, с надпис „TZD“ от едната страна и „200“ от другата страна.
Sivextro is an oval, yellow film-coated tablet imprinted with ‘TZD’ on one side and ‘200’ on the other side.
Sivextro е показан за лечение на остри бактериални инфекции на кожата и меките тъкани (acute bacterial skin and skin structure infections, ABSSSI) при възрастни (вж. точки 4.4 и 5.1).
Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4.4 and 5.1).
Sivextro трябва да се прилага само като интравенозна инфузия.
It must be administered as an intravenous infusion only.
SJS или TEN са възникнали в рамките на един месец след лекарствената комбинация и са довели до фатални изходи.
SJS or TEN occurred within one month of the medicinal combination and fatal outcomes have resulted.
SJS, ТЕН, еритема мултиформе
SJS, TEN, erythema multiforme
sjukdom
syndrome
Sjukhusförvärvad pneumoni, inklusive ventilatorassocierad pneumoni 3
including pyelonephritis3
Sjældne (mere end 1, men mindre end 10 dyr ud af 10.000 dyr)
uncommon (more than 1 but less than 10 animals in 1,000 animals)
SK-821 02 Bratislava
1231 Ljubljana
Ska inte administreras samtidigt med glukokortikoider, andra NSAIDs eller antikoagulantia.
Do not administer concurrently with glucocorticoids, other NSAIDs or with anti-coagulant agents.
Ska inte ges samtidigt med glukokortikoider, andra icke-steroida antiinflammatoriska medel (NSAIDs) eller antikoagulantia.
Do not administer concurrently with glucocorticoids, other NSAIDs or with anti-coagulant agents.
Skakas väl före användning.
Shake well before use.
Skall inte administreras samtidigt med glukokortikoider, andra NSAIDs eller antikoagulantia.
Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
Skall inte användas till djur som lider av gastrointestinala störningar, som irritation och blödning, försämrad lever-, hjärt- eller njurfunktion och blödningsrubbningar.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Skall inte användas till dräktiga eller digivande djur.
Do not use in pregnant or lactating animals.
Skall inte användas till dräktiga eller lakterande djur.
Do not use in pregnant or lactating animals.
Skall inte användas till dräktiga och lakterande ston.
Do not use in pregnant or lactating mares.
Skall inte användas till grisar yngre än 2 dagar.
Do not use in pigs less than 2 days old.
Skall inte användas till hundar som lider av gastrointestinala störningar, som irritation och blödning, försämrad lever-, hjärt- eller njurfunktion och blödningsrubbningar.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Skall inte användas till hundar som lider av magbesvär, som irritation och blödning, försämrad lever-, hjärteller njurfunktion och blödningsrubbningar.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Skall inte användas till hundar yngre än 6 veckor eller som väger mindre än 4 kg.
Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.
Skall inte användas till hundar yngre än 6 veckor eller till katter på mindre än 2 kg.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.
Skall inte användas till hundar yngre än 6 veckor.
Do not use in dogs less than 6 weeks of age.
Skall inte användas till hästar yngre än 6 veckor.
Do not use in horses less than 6 weeks of age.
Skall inte användas vid överkänslighet mot aktiv substans, eller mot något hjälpämne.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Skall inte blandas med något annat läkemedel förutom med de vacciner som nämns ovan.
Do not mix with any other veterinary medicinal products except the above mentioned vaccines.
Skall inte ges samtidigt med glukokortikoider, andra icke-steroida antiinflammatoriska medel (NSAIDs) eller antikoagulantia.
Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
Skall inte ges samtidigt med glukokortikosteroider, andra icke-steroida antiinflammatoriska läkemedel eller antikoagulantia.
Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.
Skall inte ges samtidigt med glukokortikosteroider, andra icke-steroida antiinflammatoriska läkemedel eller antikoagulantia.
Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.
Skelettproblem.
Bone problems.
SKLEPNE UGOTOVITVE O ZAHTEVKU ZA ENOLETNO TRŽNO ZAŠČITO, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
CONCLUSIONS ON THE REQUEST FOR ONE-YEAR MARKETING PROTECTION PRESENTED BY THE EUROPEAN MEDICINES AGENCY
Skupna absorpcija je bila pri psih in mačkah večja, kadar so jim zdravilo dajali s hrano.
The overall absorption was higher in dogs and cats when administered with food.
Skupna absorpcija je bila večja, kadar so zdravilo dajali s hrano.
The overall absorption was higher when administered with food.
Skupna pogostnost halucinacij in zaspanosti je bila v fazi eskalacije na splošno večja v skupini, ki je prejemala pramipeksol.
The overall incidence of hallucinations and somnolence was generally higher in the escalation phase with the pramipexole group.
Skupna pojavnost intraventrikularne krvavitve je bila 28,9-odstotna (114) pri skupini, ki so jo zdravili z iNO, v primerjavi z 22,9-odstotno (91) pri kontrolnih novorojenčkih.
The overall occurrence of intraventricular haemorrhage was 114 (28.9 %) among the iNO treated as compared to 91 (22.9 %) among the control neonates.
Skupni dnevni odmerek (mg soli)
Total Daily Dose (mg of salt)
Skupni dnevni odmerek (mg)
Total Daily Dose (mg of base)
Skupni dnevni odmerek (mg)
Total daily dose (mg)
Skupni dnevni odmerek v mga
Total daily dose in mga
Skupni holesterol (mg/dl)
TC (mg/dl)
Skupni očistek pramipeksola je približno 500 ml/min, ledvični očistek pa je približno 400 ml/min.
The total clearance of pramipexole is approximately 500 ml/min and the renal clearance is approximately 400 ml/min.
Skupno je 99,7 % bolnikov prejemalo fibrinolitike (fibrinsko specifične: 68,7 %, nefebrinsko specifične: 31,1 %), 89,5 % heparin, 78,7 % blokatorji beta, 54,7 % zaviralce angiotenzinske konvertaze in 63 % statine.
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers,
Skupno je bilo ugotovljenih 14 relevantnih primerov, ki so vsi izvirali iz obdobja po začetku trženja zdravila.
In total, 14 relevant cases, all from post-marketing sources, were identified.
Skupno število smrti pri 36. tednu je bilo nekoliko večje v skupini, ki je prejemala iNO: 53/395 (13,4 %), v primerjavi s kontrolno skupino 42/397 (10,6 %).
The overall number of death at week 36 was slightly higher in the iNO group; 53/395 (13.4 %) as compared to control 42/397 (10.6 %).
Skyldighet att vidta åtgärder efter godkännande för försäljning
Obligation to conduct post-authorisation measures
SKÄL FÖR ETT YTTERLIGARE FÖRNYAT GODKÄNNANDE
GROUNDS FOR ONE ADDITIONAL RENEWAL
Skölj noga med vatten vid oavsiktlig kontakt med ögonen.
In case of accidental contact with the eyes, rinse thoroughly with water.
SL-03680 Martin Словакия
SL-03680 Martin Slovakia
SL6 6RJ
SL6 6RJ UK
Slabinská 30, 03680 Martin Словакия
Slabinská 30, 03680 Martin Slovakia
Slabost
Nausea
SLAMF7 се открива в големи количества по повърхността на клетките на мултиплен миелом, както и на някои клетки от имунната система (клетки естествени убийци).
SLAMF7 is found in large amounts on the surface of multiple myeloma cells and on certain cells of your immune system (natural killer cells).
SLE Responder Index (Индекс на отговор при СЛЕ) измерва подобрението по отношение на активността на СЛЕ без влошаване в никоя органна система или в цялостното състояние на пациента.
The SLE Responder Index measures improvement in SLE disease activity, without worsening in any organ system, or in the patient’s overall condition.
sledování elektrokardiogramu.
(↑145% ↑187%)
sledování nežádoucích účinků
neutropenia and uveitis is warranted
Sledování v průběhu titrace
Monitoring during titration
Slentrol 5 mg /ml перорален разтвор за кучета Dirlotapide
Slentrol 5 mg/ml oral solution for dogs Dirlotapide
Slentrol 5 mg/ml перорален разтвор за кучета Dirlotapide
Slentrol 5 mg/ml oral solution for dogs Dirlotapide
Slentrol може да предизвика дразнене и възпаление на очите.
Slentrol may cause eye-irritation.
SLENTROL трябва да се прилага като част от цялостна програма за контрол на теглото, която включва подходяща диета и упражнения.
To be used as part of an overall weight management programme which also includes appropriate dietary changes and exercise practice.
Slika 1
Figure 1
Slika 1: Povprečna sprememba ocene BPI od izhodišča.
Figure 1: Mean changes from baseline in BPI scores.
Slika 2
Figure 2
Slika 3
Figure 3
Slika 4
Figure 4
Slika 5
Figure 5
Slika 6
Figure 6
Slika 7
Figure 7
Slika 8
Figure 8
Slough, Berks SL1 4DX Великобритания
Slough, Berks SL1 4DX United Kingdom
Slough, Berkshire SL1 3UH Великобритания
Slough, Berkshire SL1 3UH United Kingdom
Slovak Republic/Slovenská republika Angelini Pharma Slovenská republika s.r.o.
Slovak Republic/ Slovenská republika Angelini Pharma Slovenská republika s.r.o.
Slovenia/Slovenija Angelini Pharma d.o.o.
Slovenia/ Slovenija Angelini Pharma d.o.o.
Slovenija
Hrvatska
Slovenija
Ireland
Slovenija
Latvija
Slovenija
Polska
Slovenija
România
Slovenija
Suomi/Finland
Slovenija
Ísland
Slovenija GlaxoSmithKline d.o.o.
GlaxoSmithKline d.o.o.
Slovenija medac GmbH
Slove nija medac GmbH
Slovenská republika
Medinfar
Slovenská republika
Portugal
Slovenská republika (Slovak Republic) Eli Lilly Regional Operations GmbH Elanco Animal Health
Slovenská republika (Slovac Republic) Eli Lilly Regional Operations GmbH Elanco Animal Health
Slovenská republika Astellas Pharma s.r.o., Tel: + 421 2 4444 2157
Slovenská republika Astellas Pharma s.r.o., Tel: +421 2 4444 2157
Slovenská republika GlaxoSmithKline Slovakia s. r. o.
Slovenská republika GlaxoSmithKline Slovakia s. r.
Slovenská republika MEDA Pharma spol. s r.o.
Slovenská republika
Sluta inte att ta Emtriva utan att först prata med din läkare.
Don’t stop taking Emtriva without talking to your doctor.
Slyngediuretika hæmmer primært Na+/2Cl-/K+-transporteren fra cellens luminale side.
Loop diuretics mainly inhibit the Na+/2Cl-/K+ carrier from the luminal side of the cell.
sma a l
1.50 (0.50
sma a l
317.4 (29.9)
Smithfield, Rhode Island 02917 САЩ
Smithfield, Rhode Island 02917 U.S.A.
Smole, ki vežejo žolčne kisline
Bile acid resin
SMPR (за пациенто- година)
SMPR (per patient year)
SMR за година
SMR per Year
SMV + peg-IFN-alfa + RBV за 12 седмици, последвано от peg-IFN-alfa + RBV3 за 12 или 36 седмици; контролна група: плацебо + peg-IFN-alfa + RBV за 48 седмици
12 weeks SMV + peg-IFN-alfa + RBV, followed by 12 or 36 weeks peg-IFN-alfa + RBV3; control group: 48 weeks placebo + peg-IFN-alfa + RBV
SMV + софосбувир за 12 седмици
12 weeks SMV + sofosbuvir
Smärta och irritation i venerna
Pain and irritation of the veins
Smärta vid injektionsstället kan förekomma om injektion ges subkutant.
Pain at injection site may occur when injected subcutaneously.
Smärta vid injicering kan reduceras genom att produkten injiceras vid kylskåpstemperatur.
Injecting the product at refrigerated temperature may reduce pain at injection.
smärta, asteni
pain, asthenia
Smärtlindring i samband med kolik hos häst.
For the relief of pain associated with equine colic.
SN
SN:
SN :
SN:
SN: {номер} NN: {номер
NN: {number}
SN: {номер} NN: {номер}
SN: {number} NN: {number}
Snaygill Industrial Estate Keighley Road
Snaygill Industrial Estate Keighley Road Skipton
Snažte se snižovat tělesnou hmotnost postupným, rovnoměrným tempem asi <0,5 kg za týden.
You should aim to lose weight at a gradual, steady pace of about 0.5 kg (1 lb) per week.
Snažte se snižovat tělesnou hmotnost postupně a rovnoměrně.
You should aim to lose weight gradually and steadily.
Snemite pokrovček z viale (glejte Sliko 3).
Take the cap off the top of the vial (see Figure 3)
snižovat AUC a Cmin atazanaviru.
and Cmin of atazanavir.
SNRI (zaviralci privzema serotonina in noradrenalina), ki se uporabljajo za zdravljenje depresivnosti in/ali anksioznosti, vključno z venlafaksinom, duloksetinom.
SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram;
SNRI (инхибитори на обратното захващане на серотонина и норадреналина) се използват за лечение на депресия и/или тревожност и включват венлафаксин, дулоксетин.
SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.
Snížená chuť k jídlu
Decreased appetite
Snížená hladina protrombinu a zvýšení INR (viz bod 4.3 a 4.5)
Decreased prothrombin and increased INR (see sections 4.3 and 4.5)
snížená rozpustnost atazanaviru
reduced solubility of atazanavir
snížená srdeční frekvence
reduced heart rate
Snížené plazmatické koncentrace atazanaviru mohou být důsledkem zvýšeného pH v žaludku, pokud se antacida, včetně pufrovaných léčivých přípravků, podávají s přípravkem EVOTAZ.
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with EVOTAZ.
Snížení plazmatických koncentrací amiodaronu byl zaznamenán při jeho jednorázovém podání omezenému počtu zdravých dobrovolníků, kterým byl současně podáván orlistat .
A decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number of healthy volunteers who received orlistat concomitantly.
Snížený metabolismus CYP2C19 u intermediárních a pomalých metabolizátorů se snížila Cmax a AUC aktivního metabolitu o 30–50 % po podání 300 mg nebo 600 mg úvodní dávky a 75 mg udržovacích dávek.
Reduced CYP2C19 metabolism in intermediate and poor metabolisers decreased the Cmax and AUC of the active metabolite by 30-50% following 300- or 600-mg loading doses and 75-mg maintenance doses.
Snížený metabolismus CYP2C19 u intermediárních a pomalých metabolizátorů snížil Cmax a AUC aktivního metabolitu o 30–50 % po podání 300 mg nebo 600 mg úvodní dávky a 75 mg udržovacích dávkách.
Reduced CYP2C19 metabolism in intermediate and poor metabolisers decreased the Cmax and AUC of the active metabolite by 30-50% following 300- or 600-mg loading doses and 75-mg maintenance doses.
Sobimatus
Incompatibilities
SOC (бр.=42)
SOC (n=42)
SOC = стандартни грижи
SOC = standard of care
Sockervaddsarom Dinatriumedetat Saltsyra
Propyl parahydroxybenzoate (E216) Sodium hydroxide
Sodelovalo je vsega skupaj 670 pediatričnih kirurških bolnikov, starih od 30 dni do 16,9 leta.
A total of 670 paediatric surgical patients participated, age 30 days to 16.9 years.
Sodium benzoate 1,5 mg
Sodium benzoate 1.5 mg
Sodium benzoate 1,75 mg
Sodium benzoate 1.75 mg
Sodium benzoate 1,75 mg.
Sodium benzoate 1.75 mg.
Sodium benzoate 2 мг
Sodium benzoate 2 mg
Sodium chloride / Hydrochloric acid 4N ( за коригиране на РН) Вода за инжекции
Sodium chloride / Hydrochloric acid 4N (for pH adjustment)